Anlotinib Combined With PD-1 Inhibitors for Advanced/Metastatic Esophageal Cancer (APEC)
2021年7月24日 更新者:Jun Liu、Shanghai Chest Hospital
Treatment Patterns and Clinical Outcomes Among Patients Receiving Anlotinib in Combination With PD-1 Inhibitor for Advanced/Metastatic Esophageal Squamous Cell Carcinoma in Real-world Settings(APEC)
Efficacy and Safety of Anlotinib combined with PD-1 inhibitors as 2 or more lines treatment for Heavily Pretreated Patients With Advanced, Metastatic Squamous Cell Carcinoma of the Esophagus.
研究概览
地位
尚未招聘
条件
详细说明
The APEC study is a multi-center, retrospective ,real-world study of anlotinib combined with PD-1 inhibitors for patients with histologically confirmed advanced and metastatic esophageal squamous cell carcinoma (ESCC) that progressed after 1or more lines of therapy, conducted at 8 sites in China.
Patients received anlotinib combined with PD-1 inhibitors , every 3 weeks for up to 2 years, until progression of disease, unacceptable toxic effects occurred, or withdrawal of consent.
The primary end point was the progression-free survival (PFS)among all patients.
Secondary end points included Adverse events (AEs),objective response rate (ORR) ,duration of response (DOR), , and overall survival (OS).
Tumor response was assessed per the Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1.
研究类型
观察性的
注册 (预期的)
50
参与标准
研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。
资格标准
适合学习的年龄
18年 及以上 (成人、年长者)
接受健康志愿者
不
有资格学习的性别
全部
取样方法
非概率样本
研究人群
Patients with esophageal squamous cell carcinoma who have received anlotinib combined with PD-1 inhibitors as 2 or more lines treatment.
描述
Inclusion Criteria:
- Male or female patients aged more than 18 years old;
- ECOG PS:0-2;
- Subjects with histologically or cytologically confirmed locally advanced and/or advanced esophageal squamous cell carcinoma(ESCC);
- For local advanced or advanced ESCC, disease progression occurred after 1 or more lines systemic treatment previously;
- Have received anlotinib combined with PD-1 inhibitor treatment.
Exclusion Criteria:
- have used Anlotinib before;
- mixed with small cell cancer and/or other kinds of cancer ;
- Previously (within 5 years) or presently suffering from other malignancies;
- Symptomatic or uncontrolled brain metastases;
- Unstable systemic disease, including active infection, uncontrolled hypertension, unstable angina, congestive heart failure, or myocardial infarction within 6 months or serious cardiac arrhythmia requiring medication;
- Pregnancy or lactation. -
学习计划
本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。
研究是如何设计的?
设计细节
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
---|---|---|
Progression-Free Survival (PFS)
大体时间:6 months
|
PFS is defined as the time from the date of treatment to the first date of disease progression or death from any cause
|
6 months
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
---|---|---|
不良事件
大体时间:直到 30 天安全跟进访问
|
以不良事件作为安全性和耐受性衡量标准的参与者人数
|
直到 30 天安全跟进访问
|
Objective Response Rate (ORR)
大体时间:each 42 days up to intolerance the toxicity or PD (up to 12 months)
|
Treatment response are defined as complete response (CR), partial response (PR), stable disease (SD) and progression disease (PD) according to Response Evaluation Criteria in Solid Tumor (RECISIT criteria, version 1.1) and the percentage of patients who achieved CR, PR and SD was defined as disease control rate (DCR).
|
each 42 days up to intolerance the toxicity or PD (up to 12 months)
|
Overall Survival (OS)
大体时间:12 months
|
OS is calculated from diagnosis to death or last follow-up time
|
12 months
|
合作者和调查者
在这里您可以找到参与这项研究的人员和组织。
研究记录日期
这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。
研究主要日期
学习开始 (预期的)
2021年8月1日
初级完成 (预期的)
2021年12月31日
研究完成 (预期的)
2022年12月31日
研究注册日期
首次提交
2021年7月24日
首先提交符合 QC 标准的
2021年7月24日
首次发布 (实际的)
2021年7月30日
研究记录更新
最后更新发布 (实际的)
2021年7月30日
上次提交的符合 QC 标准的更新
2021年7月24日
最后验证
2021年7月1日
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.